icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
Gha5JZZ0EskwGv5L